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Abstract 
The cardiac ryanodine receptor (RyR2) is a Ca2+ ion channel found in the sarcoplasmic 
reticulum (SR), an intracellular membranous Ca2+ storage system. It is well known that a 
destabilization of RyR2 can lead to a Ca2+ flux out of the SR, which results in an 
overload of intracellular Ca2+; this can also lead to arrhythmias and heart failure. The 
catecholamines play a large role in the regulation of RyR2; stimulation of the β-
adrenergic receptor on the cell membrane can lead to a hyperphosphorylation of RyR2, 
making it more leaky to Ca2+. We have previously shown that strong electron donors will 
inhibit RyR2. It is hypothesized that the catecholamines, sharing a similar structure with 
other proven inhibitors of RyR2, will also inhibit RyR2. Here we confirm this hypothesis 
and show for the first time that the catecholamines, isoproterenol and epinephrine, act as 
strong electron donors and inhibit RyR2 activity at the single channel level. This data 
suggests that the catecholamines can influence RyR2 activity at two levels. This offers 
promising insight into the potential development of a new class of drugs to treat heart 
failure and arrhythmia; ones that can both prevent the hyperphosphorylation of RyR2 by 
blocking the β-adrenergic receptor, but can also directly inhibit the release of Ca2+ from 
RyR2. 
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Chapter I Introduction to Cardiac Muscle 
1.1 Muscle 
Muscles are the means by which animals move, maintain homeostasis, digest food, 
breathe, and accomplish various other tasks essential to maintain life. Contraction of 
muscle takes chemical energy and turns it into a force capable of doing mechanical work. 
Muscle comes in both the voluntary and involuntary varieties, which together make up a 
significant portion of an animal's mass. There are 3 classifications of muscle: skeletal, 
cardiac, and smooth. 
 
Both cardiac and skeletal muscles are known as striated muscle, due to the appearance of 
striations in their structure. These striations are the contractile elements of the muscle 
tissue, which appear as alternating dark and light bands when viewed under a 
microscope. Skeletal is the only example of a voluntary muscle; animals control the 
contraction via their nervous system. Cardiac and smooth are involuntary muscles.  
 
Overlapping contractile proteins in striated muscle allow for a greater force and distance 
of contraction; these are essential for physical movement of an animal and also for 
generating enough force to pump blood through the body. Although skeletal and cardiac 
muscles have similarities in their structure, they function through slightly different 
mechanisms. Smooth muscle lacks the alternating pattern of light and dark contractile 
elements; the seemingly random alignment of contractile proteins in smooth muscle 
allows it to maintain its contraction for longer periods of time.  
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1.1.1 Cardiac Muscle 
Cardiac muscle is involved in the contraction of the heart. The cells that make up the 
muscle of the heart are referred to as cardiomyocytes. The main proteins making up the 
cardiac muscle are actin and myosin; the interaction between these 2 proteins is what 
leads to contraction in muscle (See Section 1.2.4). Thick filaments are made up of many 
myosin molecules, forming a rod-like structure, with many myosin heads coming off the 
filament. These myosin heads bind to the thin filaments made up from F-actin, troponin 
and tropomyosin. The thin and thick filaments are overlapping in the muscle cell; 
underneath a microscope, regions containing overlap between the thin and thick filaments 
appear denser (A bands) and regions where just the thin filaments exist are lighter (I 
bands). Z disks serve as anchors in the I bands, where all of the thin filaments are 
attached. 
 
 
Figure 1  Space filling model showing F-actin interacting with the thick filament's 
myosin head1 
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The thin and thick elements together (sarcomere) give the muscle its striated appearance. 
Long chains of sarcomeres are referred to as myofibrils; many of these myofibrils 
together are what is known as a muscle fiber.  
 
The sarcolemma, or cell membrane, encompasses the muscle fiber. The sarcolemma is 
responsible for maintaining electrochemical gradients between the cytosol and the 
extracellular fluid. It is these electrochemical differences that are the driving force for the 
action potential and muscle contraction. 
 
The transverse tubules (T-tubules) are invaginations in the sarcolemma; they are typically 
perpendicular to the muscle fibers. The primary purpose of the T-tubule is to allow the 
action potential to propogate into the inner regions of the muscle fiber, and to activate L-
type Ca2+ channels.  The T-tubules in cardiac muscle tend to be larger and fewer in 
number than those found in skeletal muscle.  In skeletal muscle the T-tubules  are spaced 
at about 1.2µm intervals, whereas in cardiac they are at 2.5µm intervals2.  
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Figure 2 Illustration showing the structure of muscle fibers1 
 
 
1.2 The Calcium Release Channel 
 
1.2.1 The Sarcoplasmic Reticulum 
Sarcoplasmic Reticulum (SR) is a subcellular organelle whose primary role is to control 
the levels of calcium in muscle cells. The SR runs along each myofibril and wraps around 
it. There is a region of enlargement in the SR where it meets the T-tuble, known as the 
terminal cisternae.  A difference between skeletal and cardiac muscle is that in skeletal 
muscle, the T-tubules  overlap 2 terminal cisternae, creating a triadic junction, whereas 
with cardiac muscle, the T-tubule is opposed to one terminal cisternae, creating a dyadic 
junction. 
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Two different types of SR can be classified: the longitudinal SR (LSR), which runs along 
the myofibril and junctional SR (JSR), the SR that forms the terminal cisternae and 
makes a dyad or triad with the T-tubule system. The mixture of the 2 types of SR we 
refer to as crude SR (CSR).  
 
There are various proteins found both in the lumen of the SR, as well as membrane of the 
SR. The 2 main proteins responsible for calcium entering and exiting the SR lumen are 
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, and the calcium release 
channel. Ninety percent of the calcium pump is found in the longitudinal SR, whereas the 
highest density of release channel is found in the junctional SR. There is approximately 
one hundred times as much Ca2+ pump found in the SR than there is Ca2+ release channel.  
 
 
1.2.2 The Calcium Release Channel 
The calcium release channel is commonly known as the ryanodine receptor (RyR), 
because of its high affinity for the plant alkaloid ryanodine when the channel is in its 
open state3. It is the largest known ion channel, with around 5,000 amino acids and a 
molecular weight around 2.3 MDa. It is comprised of 4 identical monomers, each of 
molecular weight 565 kDa, which together form a homotetramer.  
 
There are three different isoforms of RyR which are found in many places in the body; 
however, each isoform is typically correlated to one of the three types of muscle. RyR1 is 
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primarily associated with skeletal muscle, RyR2 with cardiac muscle, and RyR3 with 
smooth muscle. The three isoforms share approximately a 70% sequence homology, 
leading to near identical three-dimensional structures.  
 
The ryanodine receptor’s three-dimensional structure was first determined by cryo-
electron microscopy methods in the mid-1990s4. Reconstructions of the 3 isomers show 
similar structure overall. There are 2 main pieces associated with the channel: A large 
cytoplasmic assembly, which consists of 4 identical monomers, each of which has been 
hypothesized to have at least fourteen distinct domains5. The cytoplasmic assembly is 
290x290Å looking from the top down, and 130Å thick. The second piece consists of a 
smaller, transmembrane assembly (TA). The TA is imbedded in the SR and connects the 
cytoplasm to the lumen inside of the SR; it measures 120x120x70Å. 
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Figure 3 Cryo-EM 3D reconstruction of RyR1 in both the open and closed states6  
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The calcium release channel is imbedded in the SR membrane and is responsible for 
release of calcium ions from the lumen of the SR. Cryo-electron microscopy has shown 
large domain changes between the open and closed states of the channel as seen in figure 
3.; it has also been a useful tool in determining binding locations for many of the 
molecules and proteins which interact with the channel.  
 
1.2.2.1 Associated Proteins with the Ryanodine Receptor 
FKBP 12: Primarily associated with RyR1, but also found in RyR2. It has a molecular 
mass of 12kDa and is found at concentrations 10x that of FKP12.6. FKBP12 stabilizes 
the closed conformation of RyR7. Removal of the FKBP has been shown to increase 
subconductance states in bilayer studies in both RyR1 and RyR28. 
FKBP12.6: Primarily associated with RyR2. It has a molecular mass of 12.6 kDa. 
Although FKBP12.6 is found at much lower concentrations than FKBP12, RyR2 has 
approximately a 500 fold greater affinity for it.  
Calmodulin (CaM): A 16.8 kDa Ca2+-binding protein, capable of binding four Ca2+ ions, 
two in each of its domains. In RyR1 CaM will stimulate the channel at low Ca2+ 
concentrations and inhibit at higher Ca2+ concentrations. In RyR2 CaM has only shown 
channel inhibition9. Recent studies have shown that mutant variations of CaM, that can 
exist in its Apo-CaM state (without Ca2+) even at high levels of Ca2+, binds in different 
domains than that of Ca2+-bound CaM10. This may account for the discrepancies in 
function between the two isoforms of RyR. 
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Protein Kinase A (PKA): A 96 kDa protein anchored to RyR2. It plays a role in the 
phosphorylation of the channel, leading to a more open or closed state.  
Junctin: A 26 kDa protein found in the junctional SR in both skeletal and cardiac 
muscle. Junctin can bind to the RyR and couple to calsequestrin.  
Triadin: A 35 kDa protein found in the junctional SR. Triadin plays a similar role to 
junctin in coupling to calsequestrin. It has also been shown that both triadin and junctin 
bind calsequestrin more strongly in the presence of low Ca2+11.  
Calsequestrin (CSQ): A 45 kDa Ca2+-binding protein. It is found in the lumen of the SR 
and each molecule of CSQ binds up to 50 Ca2+ ions with ow affinity (Kd∿1mM)12. By 
binding large amounts of Ca2+, the SR is made a much better storage system for Ca2+ than 
would otherwise be possible. 
The Dihydropyridine Receptor (DHPR): A 100 kDa L-type voltage-gated Ca2+ 
channel. It is found embedded in the T-tubule membrane and plays a key role in 
excitation-contraction coupling (See section 1.2.3). It makes direct contact with RyR1 
and is essential to its function. The association between the DHPR and RyR2 is not as 
well defined.  
PP1 and PP2A: Phosphatases associated with RyR2. 
Selenoprotein N: Appears to be responsible for sensing the cellular redox environment 
and controlling the gating of RyR113. 
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1.2.2.2 Other Modulators of the Ryanodine Receptor 
Calcium (Ca2+): The most crucial ion associated with the receptor. Calcium has a 
biphasic effect upon the RyR. At low Ca2+ concentrations (<1µM), Ca2+ stimulates the 
release of Ca2+ from RyR, a process referred to as calcium-induced calcium release 
(CICR). At higher concentrations of Ca2+ (>100µM) the RyR is inhibited8. This biphasic 
effect is attributed to there being several binding locations for Ca2+ on the receptor; one 
which stimulates the channel and has a higher affinity for Ca2+,  this is the primary 
binding site at low Ca2+. A second binding site, which inhibits when bound with Ca2+, has 
a much lower affinity so it is only populated at higher concentrations of Ca2+. 
Magnesium (Mg2+): An inhibitor of RyR, believed to compete with high affinity Ca2+ 
binding sites14. 
Glutathione (GSH): Plays a role in maintaining the redox status of cells. When an 
excess of reactive oxygen species is present, GSH can donate electrons to hydroperoxide 
resulting in a glutathione disulfide (GSSG) being formed. The ratio between GSH and 
GSSG play a role in the state of RyR15.  
Adenosine-5’-triphosphate (ATP): ATP along with other adenine nucleotides (cAMP, 
ADP, and AMP) are stimulators of RyR16. 
 
1.2.3 Excitation-Contraction Coupling  
All cells in the animal kingdom, including muscle cells, are electrically polarized. The 
electrical potential generated by the imbalance of charge on ions between the inside and 
outside of the cell is referred to as the membrane potential. In some cells, when a set 
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membrane potential is reached (threshold potential), the cell will rapidly depolarize; in 
muscle cells this leads to contraction. The process of an electrical signal being converted 
into a mechanical response is referred to as excitation-contraction coupling (ECC).  
 
The mechanism of EC coupling is slightly different in skeletal and cardiac muscle. The 
difference arises from skeletal RyRs having a direct physical interaction with the DHPR. 
Here only cardiac EC coupling will be discussed.  
 
In the heart, pacemaker cells first initiate an action potential. The action potential travels 
down the t-tubules which allow a threshold potential to be reached. This threshold 
potential depolarizes the cell allowing for an influx of Ca2+ through the DHP receptors. 
This influx of Ca2+, along with the close proximity of DHPRs to RyR2 initiates CICR. 
This generates a positive feedback system allowing for more and more Ca2+ to be 
released from the SR.  
 
 
1.2.4 Contraction of Muscle 
Once Ca2+ floods the cell upon release from the SR, troponin C, a Ca2+-binding protein 
attached to the F-actin thin filaments, binds Ca2+. Upon binding of Ca2+ a conformational 
change occurs on troponin C, this allows the myosin head to attach itself to the actin 
filament.  
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ATP binds to the myosin head and the myosin dissociates itself from the actin filament. 
ATP hydrolysis occurs, generating ADP and inorganic phosphate (Pi), as well as a 
conformational change in the myosin head. The myosin head shifts its position further 
down the actin filament and rebinds. Upon the binding of the myosin head to the actin 
filament, Pi is released. Finally, the myosin head returns back to its resting state and 
releases the ADP. This final step shifts the actin and myosin filaments relative to one 
another causing muscle contraction. This can be visualized under the microscope; upon 
muscle contraction, the Z disks will shift closer to one another. Skeletal muscle 
contraction occurs on the order of 2-5ms, while cardiac muscle contracts between 20-
50ms. 
 
1.2.5 Heart Failure and Arrhythmias Associated with RyR2 
Heart failure (HF) is the heart’s inability to pump sufficient blood through the body to 
supply the organs with enough oxygen. It was reported in 2012 that approximately 5.7 
million people living in the United States are living with heart failure17. Of these, half of 
them die within 5 years of the diagnosis. With such a high population of people being 
affected by failure, it is important to understand the mechanisms under which heart 
failure occurs, in order to both prevent and treat the disease. 
It is known that electrical instabilities in cardiac muscle is what leads to the arrhythmias, 
but how and why this occurs is still not completely understood. It has been shown that 
there is a strong correlation between the improper handling of intracellular Ca2+ and HF. 
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Improper cardiac contraction via a malfunctioning RyR2 leads to a leak in Ca2+ during 
diastole.  The leak causes a change in the normal polarization of the cardiomyocyte, 
altering the action potential in what is referred to as a delayed afterdepolarization (DAD). 
DADs lead to arrhythmias and in turn sudden cardiac death (SCD).  
Reduced cardiac output during HF is compensated for in the body by an elevation in the 
body’s catecholamine levels18. Elevated catecholamine levels, while increasing cardiac 
output, can worsen HF19. The catecholamines act indirectly on intracellular Ca2+ 
handling, triggering a receptor outside the cell, which in turn leads to a 
hyperphosphorylation of the channel (See Chapter 2). 
One hypothesis on how this hyperphosphorylation leads to a malfunctioning RyR2 has to 
do with the FK binding proteins associated with RyR2. Phosphorylation of the channel 
causes the FKBP12.6 to dissociate (although this remains controversial20), which 
destabilizes RyR221. This is likely due to an increased Ca2+-dependent activation22.   
Increased intracellular Ca2+ is not only due to the leak of Ca2+ from RyR2, but the 
SERCA pump found in cardiac SR also has reduced function. During HF, 
phospholamban (PLB), a membrane protein associated with RyR2, becomes hypo-
phosphorylated. When PLB becomes hypo-phosphorylated it inhibits the pump’s 
function. This along with the RyR2 leak leads to an increase in intracellular Ca2+ levels, 
and affects contractility23,24. 
 
14 
 
1.2.5.1 Catecholaminergic Polymorphic Ventricular Tachycardia  
Catecholamines not only play a role in individuals with HF, but they play an especially 
important role in individuals with catecholaminergic polymorphic ventricular tachycardia 
(CPVT). During the “Fight-or-Flight Response,” elevated catecholamines increase heart 
rate, the strength contraction of the heart, and increased airflow to the lungs, in the 
presence of perceived danger. Under normal conditions this response is an evolutionary 
advantage; however, these elevated catecholamine levels in individuals (CPVT), a 
genetic disease involving a mutation on either RyR2 (CPVT1) or the associated protein 
calsequestrin (CPVT2), can lead to arrhythmias and heart failure. CPVT is typically 
treated with antagonists of the β-adrenergic Receptor (β-Blockers), such as carvedilol; 
these compounds bind to the β-adrenergic receptor, preventing agonists of the receptor 
from binding. 
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Chapter II Catecholamines 
2.1 Introduction to Catecholamines 
Catecholamines are an organic compound made up of 2 main parts; a benzene ring with 2 
hydroxyl side groups referred to as a catechol, as well as an amine side chain. There are 
both synthetic and naturally occurring catecholamines, all sharing a similar structure. In 
the human body, the most abundant of the catecholamines include: epinephrine, 
dopamine, and norepinephrine. This work will focus on the catecholamine epinephrine as 
well as a non-natural catecholamine, isoproterenol, which shares a similar structure with 
epinephrine.  
 
2.2 Biosynthesis of Catecholamines 
In the body, the first compound in the biosynthetic pathway is typically the amino acid L-
tyrosine. In the liver, the process is started with phenylalanine being converted into 
tyrosine. Tyrosine hydroxylase, an enzyme, uses molecular oxygen and tyrosine 
substrates along with biopterin, a coenzyme, to add a hydroxyl group to L-tyrosine to 
produce 3,4-dihydroxy-l-phenylalanine (l-DOPA). It is thought that tyrosine hydroxylase 
provides the rate limiting step in the synthesis of catecholamines25.  
The next step in the pathway is DOPA decarboxylase, often called aromatic L-amino acid 
decarboxylase, converting L-DOPA into dopamine and CO2. Dopamine is the first of the 
bodies catecholamines synthesized. For locations in the body such as the substantia nigra 
and ventral tegmental area of the brainstem, the process stops here, so that dopamine can 
be utilized.   
16 
 
 
Further along the pathway molecular oxygen and dopamine β-hydroxylase are used to 
convert dopamine into norepinephrine. Regions of the body containing the dopamine β-
hydroxylase to make this conversion are referred to as, “noradrenergic.” Finally, 
norepinephrine gains a methyl group from S-adenosylmethionine, being catalyzed by 
phenylethanolamine N-methylTransferase, yielding epinephrine and homocysteine. The 
phenylethanolamine N-methylTransferase is found in several locations of the body 
including neurons in the brainstem and in adrenal cells.  
17 
 
 
Figure 4 Biosynthesis of Catecholamines26 
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2. 3 Catecholamine Function in the Body  
The catecholamines are often referred to as beta-adrenergic agonists due to their 
activation of the beta-adrenergic receptor, a G protein-coupled receptor located on the 
cellular membrane. There are three types of Beta-adrenergic receptors: β1, β2, and β3. β1 
receptors are found primarily in cardiac muscle, but are also found in kidney and stomach 
tissue. When the β1-adrenergic receptor is activated it activates adenylyl cyclase activity 
within the cell, which in turn stimulates calcium release from the ryanodine receptor 
thereby causing cardiac muscle contraction. The β2-adrenergic receptor is found 
primarily in smooth muscle. When activated, β2-receptors also stimulate adenyl cyclase 
activity; however, in smooth muscle this lowers the intracellular calcium levels, thereby 
causing the dilation of the muscle. The β3-adrenergic receptor is found primarily in 
adipose tissue and plays a role in the regulation of thermogenesis, as well as lipolysis.  
 
This thesis focuses on the role of catecholamines in cardiac tissue, therefore only the β1-
adrenergic receptor will be discussed in detail.  
 
 
2.4 Stimulation of the β1-Adrenergic Receptor 
The β1-adrengeric receptor is coupled to a G protein which spans the cellular membrane 
of cardiac myocytes. When an agonist of this receptor, such as epinephrine, binds to the 
receptor, it causes one of the G proteins subunits within the cell to activate adenylyl 
cyclase. The adenylyl cyclase, once activated, catalyzes the conversion of ATP into 3’,5’-
 cyclic AMP (cAMP). The elevated 
an intracellular enzyme whose activity depends upon the level 
Protein kinase A, once activated,
known as phosphorylation;
Hyperphosphorylation of RyR2 leads to a more open state
 
2.5 Studied Compounds
 
2.5.1 Epinephrine 
 
Figure 
Epinephrine (adrenaline outside the U.S.
the adrenal gland by Polish physiologist Napolean Cybulski.
number of locations in the body including: the adrenal medulla, chromaffin cells, and 
neurons in the central nervous system.
part of the body and be utilized in another 
 
19 
cAMP levels within the cell activate protein kinase A, 
of cAMP within the cell. 
 adds phosphate groups to other proteins in a p
 leading to hyperphosphorylation of RyR2. 
 of the channel.
 
 
5 Chemical structure of epinephrine 
 
) was first discovered in 1895 in extracts from 
 It can be synthesized in a 
 The ability of epinephrine to be produced in one 
classifies it as a hormone.   
rocess 
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Epinephrine is naturally occurring, with a molecular weight of 183.2g/mol and existing at 
typical concentrations of a few nanomolar27. The half-life of epinephrine in blood plasma 
is on the order of 2 minutes, but is constantly being produced. In the early 1900s 
epinephrine was used as a bronchodilator in asthma patients. It is widely used in medical 
fields to treat a number of conditions including cardiac arrest and anaphylaxis. This 
compound increases the strength of contractions (positive inotrope) inside of the heart. It 
also increases the heart rate (positive chronotrope).  
 
Epinephrine’s effect on both the airways and heart makes it the key hormone in the 
“fight-or-flight response.” This physiological reaction prepares one’s body to either flee, 
or stay and fight in the presence of danger.  
 
2.5.2 Isoproterenol 
 
 
Figure 6 Chemical Structure of isoproterenol 
 
Isoproterenol (Isoprenaline outside the U.S.) was developed in 1941 and is not found 
naturally in the body. It has a molecular weight of 211.3g/mol. Like epinephrine, 
isoproterenol is an agonist of the β-adrenergic receptor; however, unlike epinephrine it 
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does not stimulate the α-adrenergic receptors, which lead to vasoconstriction of the veins 
and arteries; this made it an ideal drug for the treatment of asthma for a time before the 
release of albuterol, which is more selective for the β2-adrenergic receptor, making it a 
better treatment of the airways.  
 
Isoproterenol has a biphasic half-life when administered to patients, with a first phase 
lasting only a few minutes and a second phase lasting up to 5 hours. It can either be 
administered intravenously or by aerosol to the body. 
 
 Isoproterenol is an activator of all three types of β-adrenergic receptors, the affinity of β1 
and β2 for Isoproterenol is greater than that of epinephrine, β3 receptors share about an 
equal affinity for the two catecholamines. Isoproterenol’s primary use in the medical field 
is in its activation of the β1-adrenergic receptor, which aids in the treatment of 
bradycardia (a heart rate below 60BPM). Isoproterenol acts as both a positive 
chronotrope and positive inotrope in cardiac muscle.  
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Chapter III Methods and Materials 
3.1 Materials 
 
3.1.1 Cardiac SR Preparation 
Sheep heart SR isolation follows a modified protocol from Williams 199028. Sheep hearts 
were removed and rinsed of excess blood from anesthetized sheep. The sheep heart was 
stored in an ice cold homogenization buffer containing: 300mM Sucrose, 10mM PIPES, 
0.5mM PMSF, 1µg/mL Leupeptin at PH 7.4. Upon arrival to the laboratory the heart was 
dissected in a cold room, the atria along with extra fatty tissue were discarded.  
 
Half (approximately 40g) of the ventricles of the heart were cut into cm3 pieces and 
placed into 500mL of the homogenization buffer. The pieces were homogenized in a 
blender for 20 seconds at top speed, then for another 20 seconds after a 30 second wait 
period. The rest of the heart was homogenized following the same process. 
 
The homogenates were combined and poured into 6 Type-19 rotor tubes and were 
centrifuged for 20 minutes at 9,000g in a Beckman Type-19 Rotor. The supernatant was 
filtered through 2 layers of cheesecloth and poured into 6 Type-19 tubes and centrifuged 
at 44,000g for 75 minutes in a Beckman Type-19 rotor. Supernatant was discarded and 
the pellet was placed into a resuspension buffer containing: 400mM KCl, 300mM 
Sucrose, 0.5mM MgCl2, .5mM CaCl2, .5mM EGTA, .5mM PMSF, 1µg/mL Leupeptin, 
25mM PIPES at pH 7.0. The solution was all poured into one Type-60 centrifuge tube 
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and centrifuged at 50,000 rpms for 30 minutes. The pellet was collected and added to the 
resuspension buffer. The solution was homogenized using a glass homogenizer and 
stored in 300µL aliquots in liquid nitrogen until use in experiments. 
 
3.1.2 Determination of Protein Concentration 
Cardiac SR protein concentration is measured using the method developed by Kalckar29. 
The protein backbone has a maximum absorbance peak at 230nm and the amino acids 
tyrosine and tryptophan peak at 280nm. Using an Agilent 8453 UV-Visible 
spectrophotometer, the absorbance at three wavelengths was measured. Using the 
following two equations along with the absorbance at 260nm (to correct for nucleic 
acids), protein concentration is determined: 
 
                                   
)(74.0)(45.1][ 260280/ AbsAbsSR mlmg −=
                             (eqn 3.1) 
 
                                    
)(075.0)(185.0][ 260230/ AbsAbsSR mlmg −=
                        (eqn 3.2) 
3.2 Planar Lipid Bilayer 
The majority of work in this thesis consists of work done incorporating SR vesicles into a 
planar lipid bilayer. Incorporation of ion channels into artificial planar lipid bilayers 
allows for the kinetics of single ion channels to be studied. It also provides an extremely 
useful tool in studying how various compounds and proteins affect the gating of the 
channel. 
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3.2.1 Method 
Two chambers, comprised of either acetyl or delrin, are separated by a 100-200µm 
aperture. The aperture is created in one of three ways: by drilling with a 100-200µm drill 
bit, sparking through the delrin or acetyl barrier between the chambers, or a combination 
of drilling and sparking through the created aperture. The wall separating the two 
chambers is on the order of the size of the aperture itself. It has been reported that having 
a hole on the order of the wall size will help promote fusion of proteins into the planar 
lipid bilayer30. 
 
The two chambers are filled with an aqueous solution of unequal concentration and 
volumes. The Trans (Luminal) chamber is filled with 650µL of buffer consisting of 
25mM HEPES and 40mM CsMeSO4 at pH 7.4. The CIS (Cytoplasmic) chamber is filled 
with 800µL of buffer consisting of 25mM HEPES, and 400mM CsMeSO4 at pH 7.4. The 
unequal volumes create equals levels of fluid between the two chambers, reducing any 
hydrostatic pressure at the aperture between the two chambers.   
Two electrically conducting salt bridges (Agarose, 4 M CsCl) connect the two chambers 
to two Ag/AgCl electrodes. The electrodes pass into a preamp which then runs into a 
Warner BC-525A amplifier. The amplifier passes its signal into an Axon Instruments 
Digidata 1322A digitizer and signals are recorded in Axon software (pClamp 9.0, 
ClampEx patch clamp chart recorder). 
  
 Bilayers are formed between the two
A lipid mixture consisting of a 5:3:2 mix of PE:PS:PC (PE: 1,2
Phosphoethanolamine; PS: 1,2
Dioleoyl-sn-Glycero-3-phosphocholine) (AVANTI) is m
of 33.3mg/ml. A rounded
dragged over the hole separating the two
separated by a layer of decane between them
monolayers to form into a bilay
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Figure 7 Bilayer Setup 
 chambers using the film drainage method
-Dioleoyl-
-Dioleoyl-sn-Glycero-3[phosphor-L-Serine]; PC: 1,2
ade in decane at a concentration 
 glass capillary tube is then dipped into the lipid mix and 
 chambers. Two monolayers are formed 
. The pressure from the salt bath causes the 
er.   
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Formation and quality of the bilayer is determined by tracking the capacitance of the 
aperture. Square waves are indicative of good bilayers; a saw tooth capacitance is an 
indication of a leak across the bilayer. The bilayer capacitance is also a measure of the 
thickness of the bilayer; the capacitance is inversely proportional to the thickness of the 
bilayer.  
 
Crude cardiac SR vesicles are homogenized in 300mM Sucrose, 400mM CsMeSO4 and 
added to the CIS chamber (final protein concentration: 10-40µg/mL). A holding potential 
of +36mV is set, which promotes fusion of SR vesicles. Once fusion occurs, the Trans 
bath is brought up to 400mM CsMeSO4 and the holding potential is set at -36mV. 
Vesicle fusion occurs in such a way such that the cytoplasmic side of the RyR faces the 
Cis chamber32.  
 
When the channel is in an open state, Cs+ ions are able to pass through the channel; the 
conductance of the channel is monitored and recorded. Cs+ is used as the current carrying 
ion through the channel for several reasons:  
 
• The conductance of the RyR is higher for Cs+ than Ca2+33
.
 
• Cs+ does not modulate the channel in the same way that Ca2+ does34.  
• Finally, K+ channels found in the SR are inhibited by high concentrations of 
Cs+35; this makes K+ channels distinguishable from RyR channels. 
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Subsequent recordings are made for no less than one minute each. Following each 
recording a measured concentration of compound being tested (made up fresh each day) 
is added and magnetic stir bars mix the solution for 30 seconds. Each recording of 
channel activity at the various compound concentrations is analyzed. The entire bilayer 
set-up sits in an aluminum cage to reduce outside noise.  
 
3.2.2 Analysis 
 
3.2.2.1 Event Detection 
The Clampfit 9.0 software is mostly automated, the primary analysis tool used in 
Clampfit 9.0 is creating an events list using the half-amplitude threshold technique. A 
baseline is first set representing the channels closed state; a second level is then set 
representing the channel in its open state. In cases where multiple channels are present, 
2nd and 3rd open levels may be set. The half-amplitude threshold technique distinguishes 
any event that is at least half of the open state level as an open event. Statistical analysis 
of the event list is then used to determine properties of the channel.  
 
3.2.2.2 Open Probability 
Open probability (P0) of the channel represents the probability of the channel being in the 
conducting (open) state. A channel that is in a completely closed state will have a P0 of 
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zero, while a channel in a completely open state will have a P0 of 1. P0 is calculated as the 
ratio of the total time open to the total time of the recording.  
 
                                                        
CTT
TP
+
=
0
0
0                                                    (eqn 3.3) 
Where: T0=Nτ0, TC=NτC 
 
3.2.2.3 Open and Closed Dwell Times 
A list of dwell times for each level set is generated in the events window. The dwell time 
is a representation of the time spent during each event, or the time spend at one level 
before changing to a different level. The channel’s P0 depends upon three key factors; the 
open dwell time (τO), the closed dwell time (τC), and the frequency of events. It is for this 
reason that open and closed times must be analyzed to determine the kinetics of the 
gating.  
 
Logarithmic histograms of the number of events vs. the dwell time are generated in the 
Clampfit 9.0 software. The histogram is fit to determine average τO and τC times.  
 
3.2.2.4 Student T-Test 
A t-test was applied to data for open and closed times between the control and varying 
concentrations of tested compound.  
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Where n1,n2, SX1, SX2, X1, and X2 are the sample size, standard deviation, and mean 
value for the 2 concentrations of compound being compared. 
 
From the t-test p-values between concentrations were calculated. The p-value is a 
measure of the statistical significance of the data. Here, a p-value equal or less than .05 is 
considered statistically significant.  
 
3.3 Electron Donor/Acceptor Assay 
Methylene blue (MB) is a dye that when illuminated with light will produce both dye 
anion and a dye cation radicals. Under normal circumstances, with no electron donor or 
acceptors present, the dye anion and cation will quickly recombine. If an electron donor 
is present, the electrons from the donor will pass to the dye cation, which will in turn 
increase the amount of dye anion radical present in the solution. When two dye anions 
combine, methylene blue bleaches. When dye anions pass electrons to O2, superoxide is 
generated. 
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XTT is a compound whose spectrum changes increasing absorbance at 470nm by 
reacting with superoxide. The more superoxide that is present, the larger the increased 
absorbance at 470nm. With 50µM XTT, varying concentrations of electron donor, 10µM 
MB, oxygen, and light, electron donor properties of a given compound can be quantified 
by monitoring the spectrum change in XTT, as a function of time. 
 
 
 
Figure 8 Schematic showing the process of measuring electron donor/acceptor 
properties36 
 
 
3.4 Ryanodine Binding Assays 
Ryanodine is an alkaloid found in the plant Ryania Speciosa. It binds with very high 
affinity to the ryanodine receptor, and at low micromolar concentrations, can lock the 
channel in a half open state.   
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Nanomolar levels of tritium labeled Ryanodine ([3H]ryanodine) bind to the ryanodine 
receptor when it  is in an open state. This gives it a power of being a strong molecular 
probe to assay the open state of the channel.  By adding varying concentrations of 
inhibitors or activators of the channel, several different assays involving binding of 
[3H]ryanodine can be performed. 
3.4.1 Initial Rate of Ryanodine Binding 
Varying concentrations of either isoproterenol or epinephrine were combined in test tubes 
containing: 250mM KCl, 15mM NaCl, 20mM PIPES, 50uM Ca2+, .5mg/mL crude 
cardiac SR, 13nM unlabeled ryanodine at pH 7.4. The test tubes were placed in a hot bath 
at 37˚C and the reaction is initiated by the addition of 2nM [3H]ryanodine to the test tubes 
at varying time points. For isoproterenol, the reaction was terminated at times 5, 10, 15, 
20, 25, and 30 minutes. For epinephrine only four time points were used: 5, 10, 15, and 
20 minutes.  
The reaction was quenched by rapid filtration using a Brandel cell harvester and filtering 
through Whatman glass fiber filters. The filters were subsequently washed with a buffer 
containing: 250mM KCL, 20mM TRIS, 15mM NaCl, 100uM CaCl2 at pH 7.4. Filters 
were placed in an oven at 50˚C for two hours, at which point 3mL of CytoScint 
scintillation fluid was added and the solution was agitated for at least 1 hour.  
A Beckman LS 6000 scintillation counter was used to measure the levels of 
[3H]ryanodine present in each sample. The total activity was measured by adding the 
same amount of [3H]ryanodine used in the experiment directly to the scintillation fluid 
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and measuring activity. Nonspecific binding was also measured with 200nM unlabeled 
ryanodine and 4mM EGTA. 
In the initial rate of ryanodine binding assay it is anticipated that inhibitors of the channel 
decrease the amount of binding that occurs over a given period of time. Channel 
stimulators have the opposite effect; the channel is more open, therefore allowing more 
ryanodine binding to occur. 
 
3.4.2 Ca2+-Dependence Ryanodine Binding Assay 
Ca2+ dependent ryanodine binding was measured with 10µM isoproterenol following a 
similar overall method to the initial rates binding assay. Here, drug concentration is kept 
constant and the Ca2+ concentration is varied. A control is also performed with the same 
concentrations of Ca2+ but with no drug present. The incubation at 37˚C is carried out for 
a period of three house and assaying of the activity is performed the same as the initial 
rate assay. 
Rise in ryanodine binding can be seen in varying concentrations Ca2+ because Ca2+ is 
itself a modulator of the openness of the channel. A compound that is an inhibitor may 
shift the Ca2+ dependence of RyR2 so that more Ca2+ will be needed to reach maximal 
binding (this would be illustrated by a shift of the curve to the right). A channel activator 
may lower the Ca2+ dependence, which can be seen by a shift in the curve to the left. In 
RyR2, the Ca2+ dependence is very abrupt, binding goes from a minimum to a maximum 
over a very small range of Ca2+ concentrations. 
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Chapter IV Results 
4.1 Electron Donor Properties of Studied Catecholamines 
 
4.1.1 Isoproterenol Displays Strong Electron Donor Properties 
Isoproterenol was assayed for its ability to donate electrons as explained in the methods 
section. Concentrations ranging from 0-100µM isoproterenol were tested and the 
reduction of XTT vs. time for each concentration was plotted. Figure 9 shows data from a 
total of three experiments, averaged and fit to a 2-parameter exponential rise to 
maximum:  
 
                                                     
( )dtecy −−= 1
                                                     (eqn 4.1) 
 
The standard deviation was plotted for each data point from the 3 experiments. The 
experiment was performed at pH 7.4 to mimic the condition performed in the planar lipid 
bilayer. 
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Figure 9 Electron donor properties of isoproterenol 
Isoproterenol displays strong electron donor properties in 1mM Tris Buffer at pH 7.4, 
containing 10µM MB, and 50µM XTT. Reduction of XTT was measured as an increase 
in the absorbance at 470nm. Each data point is an average of 3 experiments ± the 
standard deviation. 
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4.1.2. Epinephrine Displays Strong Electron Donor Properties 
Epinephrine was assayed for its ability to donate electrons as explained in the methods 
section. Concentrations ranging from 0-100µM of epinephrine were tested and the 
reduction of XTT vs. time for each concentration was plotted. Figure 10 shows data from 
a total of three experiments, averaged and fit to a 2-parameter exponential rise to 
maximum. The standard deviation was plotted for each data point from the 3 
experiments. The experiment was performed at pH 7.4 to mimic the condition performed 
in the planar lipid bilayer. 
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Figure 10 Electron donor properties of epinephrine 
Epinephrine displays strong electron donor properties in 1mM Tris Buffer at pH 7.4, 
containing 10µM MB, and 50µM XTT. Reduction of XTT was measured as an increase 
in the absorbance at 470nm. Each data point is an average of 3 experiments ± the 
standard deviation. 
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4.1.3. Comparison of Electron Donor Properties 
The initial rates of XTT reduction were calculated using the 2-parameter exponential rise 
along with the values of c and d generated from eqn. 4.1 in SigmaPlot 9.0. The initial 
rates vs. concentration of concentrations for both isoproterenol and epinephrine were 
plotted in figure 11, and fitted to the Michaelis-Menten equation. 
                                                  
[ ]
[ ]SK
SVV
d +
= max
                                                        
(eqn 4.2) 
Where: V=reaction rate, [S]=substrate concentration, Vmax=maximum rate, and Kd=the 
concentration at half maximal rate. 
Standard error for the initial rate was calculated and plotted for each data point. The two 
donors show very similar strengths; half maximal donor activities were calculated from 
the fit for epinephrine and isoproterenol to be 17.5µM and 24.3µM respectively.
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Figure 11 Comparison of the electron donor properties of epinephrine and 
isoproterenol 
1mM Tris buffer, containing 10µM MB, 50µM XTT at pH 7.4. Initial rates of XTT 
reduction were calculated and plotted using a 4-parameter logistic fit. Each point 
represents 3 experiments averaged ± the standard deviation. 
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4.2 RyR2 Inhibition by Isoproterenol 
Isoproterenol’s effect on RyR2 was tested in the planar lipid bilayer. All experiments 
were done in the presence of 410nM Ca2+ (calculated from Bound and Determined, 
BAD). Isoproterenol was tested in a dose dependent manner ranging in concentrations of 
100nM-7uM. A total of 8 experiments were performed under identical conditions. 
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Figure 12 Representative single channel recordings of isoproterenol 
Two second representative traces of RyR2 inhibition by isoproterenol. A channel opening 
is indicated by a downward fluctuation. A) 410nM Ca2+ (P0=0.50) B) 100nM 
Isoproterenol (P0=0.44) C) 300nM Isoproterenol (P0=0.26) D) 500nM Isoproterenol 
(P0=0.11) E) 1µM Isoproterenol (P0=0.06) 
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Figure 13 shows the concentration-dependent inhibition of single channel activity 
induced by isoproterenol. Normalized P0 was plotted vs. isoproterenol concentration. A 
4-parameter logistic plot was used to fit the data:  
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                                                  (eqn 4.3) 
The IC50 from the fit was determined to be 210nM. The IC50 is a measure of the 
compounds potency as a channel inhibitor; it represents the concentration at which the 
channel is half maximally inhibited. As can be seen from figure 13, the channel was 
never able to be fully closed by isoproterenol, making isoproterenol a partial antagonist 
of RyR2. 
Ruthenium Red (R.R.), an inorganic dye that has been shown to completely block the 
ryanodine receptor when added to its cytoplasmic face, was added at the termination of 
each experiment when channel activity was still present. This is to ensure that the 
cytoplasmic face is facing the Cis chamber, as well as to ensure that the gating being 
observed is the ryanodine receptor and not some other ion channel present in the SR. In 
all of these experiments, 10µM R.R. decreases the P0 to zero. 
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Figure 13 RyR2 inhibition by Isoproterenol 
Control recordings at 410nM Ca2+ were normalized to 1. Average P0 with standard error 
before normalization was 0.50±0.06. Each point represents the average of 8 experiments 
± standard error. 
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4.3 RyR2 Inhibition by Epinephrine 
Planar lipid bilayer experiments were performed to test Epinephrine’s potency on RyR2. 
410nM free Ca2+ was used (calculated using BAD).  Epinephrine concentrations ranging 
from 100nM-30uM were tested in a total of 6 experiments. Standard error bars were 
generated and the IC50 value was determined using the same method as used for 
isoproterenol.  
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Figure 14 Representative single channel recordings of epinephrine 
Two second traces showing dose-dependent inhibition by epinephrine. Two 
channels can be distinctly identified in traces A and B. A channel opening is indicated by 
a downward fluctuation. A) 410nM Ca2+ (P0=1.3) B) 1µM Epinephrine (P0=0.88) C) 
3µM Epinephrine (P0=0.40) D) 5µM Epinephrine (P0=0.23) E) 10µM Epinephrine 
(P0=0.15) 
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Figure 15 shows the dose-dependent response of normalized RyR2 open probability vs. 
epinephrine concentration. Like isoproterenol, epinephrine displays strong inhibition of 
RyR2 characteristics. The IC50 was determined to be 310nM. Epinephrine at high 
concentrations (30µM) is more effective in inhibiting channel activity than is 
isoproterenol. However, neither compound completely closes down the channel. They are 
both partial antagonists of RyR2 activity. Once again, 10µM RR was added at the 
termination of each experiment. 
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Figure 15 RyR2 inhibition by epinephrine 
Control recordings at 410nM Ca2+ were normalized to 1. Average P0 with standard error 
before normalization was 0.56±0.09. Each point represents the average of 6 experiments 
± standard error. 
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4.4 Dwell Times 
 
4.4.1 Isoproterenol Increases the Closed Time of RyR2 
Open and closed dwell times were calculated for isoproterenol as described in the 
methods section. Figure 16 shows normalized open times for varying concentrations of 
isoproterenol; open time decreases slightly. The p-values at 500nM and5µM 
isoproterenol for the open time were determined to be 0.14 and 0.08 respectively, 
indicating a statistically insignificant result. However, fluctuations in the open time are 
hard to measure due to the already short open time of control recordings (∿1ms) and the 
resolution to which they can be measured; this leaves a level of uncertainty as to whether 
the measurements made in this experiment for the open times actually reflect the open 
time of the channel. 
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Figure 16 Open times of RyR2 with isoproterenol 
Open time (τO) of single channel measurements at varying concentrations of 
isoproterenol. Isoproterenol slightly lowers the open time of the channel. Control 
recordings (410nM Ca2+) were normalized to one. Average τ0 with standard error (n=7) 
prior to normalization was 1.15±0.22 ms. All data is the average of 7 experiments 
normalized as the percent of control ± the standard error. 
  
 
 
49 
 
Figure 17 shows the normalized closed times as a function of isoproterenol. Closed time 
dramatically increases as increasing concentrations of isoproterenol is added. This means 
that isoproterenol’s inhibition of RyR2 is mainly due to an increase in the closed time of 
the channel. The p-values at 500nM and 5µM isoproterenol were determined to be 0.02 
and 0.01 respectively, making the epinephrine’s effect of increasing the closed durations 
statistically significant. 
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Figure 17 Closed times of RyR2 with isoproterenol 
Closed times of single channel measurements at varying concentrations of isoproterenol. 
Isoproterenol mainly decreases the open probability by increasing the closed time (τC). 
Control recordings (410nM Ca2+) were normalized to one. Average τC with standard error 
(n=7) prior to normalization was 2.35±0.47 ms All data is the average of 7 experiments 
normalized as the percent of control ± the standard error. 
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4.4.2 Epinephrine Increases the Closed Time of the Channel 
Epinephrine open and closed times were calculated in the same way as isoproterenol. 
Figure 18 shows a slight decrease in the open times as epinephrine concentration 
increases. The p-values at 500nM and 5µM epinephrine for the open time were 
determined to be 0.41 and 0.18 respectively, indicating a statistically insignificant result. 
Once again, these measurements are at the time resolution limit of our setup, so it is 
unclear if this data reflects actual open times. 
Figure 19 shows that like isopoterenol, epinephrine mainly decreases the open probability 
of the channel by increasing the amount of time the channel is in the closed state. The p-
values at 500nM and 5µM epinephrine were determined to be 0.04 and 0.02 respectively, 
making the epinephrine’s effect of increasing the closed durations statistically significant.  
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Figure 18 Open times of RyR2 with epinephrine 
Open times of single channel measurements at varying concentrations of epinephrine. 
Epinephrine slightly lowers the open time (τ0) of the channel. Control recordings (410nM 
Ca2+) were normalized to one. Average τ0 with standard error (n=5) prior to normalization 
was 0.97±0.13 ms All data is the average of 5 experiments normalized as the percent of 
control ± the standard error.  
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Figure 19 Closed times of RyR2 with epinephrine 
Closed times (τC) of single channel measurements at varying concentrations of 
epinephrine. Epinephrine mainly decreases the open probability by increasing the closed 
time. Control recordings (410nM Ca2+) were normalized to one. Average τC with standard 
error (n=5) prior to normalization was 1.78±0.45 ms All data is the average of 5 
experiments normalized as the percent of control ± the standard error. 
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4.5 Ryanodine Binding is Unaffected by Isoproterenol and Epinephrine 
Initial rate experiments were performed for both isoproterenol and epinephrine as 
described in the methods section. Despite both compounds being strong inhibitors of 
RyR2 at the single channel level, they display no strong trends in the inhibition or 
stimulation in the initial rates of ryanodine binding. 
As can be seen in figure 20, the rate of ryanodine binding is not sensitive to the 
isoproterenol concentration. All concentration tested start and end at roughly the same 
level as the control experiment (50µM Ca2+, no drug). This indicates that the channels 
remained in roughly the same open percentage for all concentrations of isoproterenol as 
well as the control. 
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Figure 20 Isoproterenol does not affect the rate of ryanodine binding 
Initial rate of ryanodine binding vs. isoproterenol concentration. No significant changes 
in the amount of ryanodine binding over time are observed as a function of 
[isoproterenol]. 
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Figure 21 shows a similar trend for epinephrine compared to that seen with isoproterenol. 
The amount of binding increased in a linear manner over the 4 time points used. All 
traces roughly start and end at the same point as the control (50µM Ca2+, no drug). Once 
again, this is indicative of epinephrine of having no inhibitory effect on ryanodine 
binding.  
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Figure 21 Epinephrine does not affect the rate of ryanodine binding 
Initial rate of ryanodine binding vs. epinephrine concentration. No significant changes in 
the amount of ryanodine binding over time are observed as a function of [epinephrine]. 
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In addition to the initial rates experiments, a Ca2+ dependence experiment was carried out 
both with and without 10µM isoproternol. Figure 22 shows a sharp rise of ryanodine 
binding over a small range of Ca2+ concentrations for both traces. There is no significant 
shift of the curve between the control and the 10µM isoproterenol. This is once again 
indicative of isoproterenol not having an effect on the openness of the channel in 
ryanodine binding type experiments. 
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Figure 22 Isoproterenol Ca2+ dependent ryanodine binding 
Ca2+-dependence equilibrium binding with and without 10µM isoproterenol. No 
significant shift in the Ca2+-dependence can be seen.  
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Chapter V Conclusions and Discussion 
The role of catecholamies has been studied since the early 1900s and their function in the 
body is thought to be well understood. In this thesis, the effect of two catecholamines, 
epinephrine and isoproterenol, acting directly upon cardiac ryanodine receptor has been 
examined for the first time.  
We have shown that both isoproterenol and epinephrine act as strong electron donors. 
The concentrations at which epinephrine and isoproterenol half maximally act as electron 
donors are 17.5µM and 24.3µM respectively. We have also shown that these two 
compounds are potent inhibitors of single channels in the planar lipid bilayer. Bilayer 
studies performed produced IC50 values for epinephrine and isoproterenol of 310nM and 
210nM respectively. We have shown that the primary means of inhibition is an increase 
in the overall closed time of the channel. P-values calculated around and much higher 
than the IC50, yielded statistically significant results for the closed times. It is unclear 
whether these compounds also have an effect on the open time of the channel. P-values 
calculated for the open times yielded non-significant results, but measurements are being 
made at the time resolution our system. 
It has previously been shown that inhibitors of the ryanodine receptor tend to act as 
electron donors, while activators of the channel tend to be electron acceptors37. Here, this 
hypothesis is confirmed for the two compounds studied. Both compounds share very 
similar electron donor properties as well as similar inhibition of RyR2 in the planar lipid 
bilayer. 
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These compounds, although strong inhibitors in the bilayer, had no effect on ryanodine 
binding experiments. Initial rates of binding indicated that the channels remained in 
roughly the same open percentage over all concentrations assayed. This is not the first 
time our lab has encountered this apparent dilemma; prior compounds tested, which have 
shown strong potency in the bilayer have had no effect on ryanodine binding. 
 One possible explanation to account for this is the means by which these catecholamines 
inhibit the channel. Ryanodine binds to the channel when it is in an open state. We have 
shown that these compounds do not significantly impact the duration of the open time of 
the channel. It is possible that without significantly altering the open time of the channel, 
the total amount of ryanodine binding will remain a constant. Inhibition of ryanodine 
binding may require a significant decrease in the open time of the channel.   
In the body, catecholamines activate the ryanodine receptor via a non-direct interaction 
that is initiated outside of the cell. Epinephrine is hydrophilic, making it unlikely that it is 
able to cross the hydrophobic plasma membrane. Isoproterenol, which is not naturally 
produced, is also hydrophilic.  This indicates that is unlikely that epinephrine or 
isoproterenol have a direct interaction on RyR2 when administered, or produced in the 
body. 
It is known that heart failure is associated with a RyR2 leak thought to be caused by a 
hyperphosphorylation of the channel37. This hyperphosphorylation hypotheis remains 
controversial; it has been shown that PKA-phosphorylation doesnot affect Ca2+ sparks in 
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permeabilized myocytes38. Regardless, β-adrenergic receptor stimulation does seem to 
initiate a release of Ca2+ from RyR2, which in turn can lead to arrhythmia.  
Two therapeutic ways to treat patients with arrhythmia can be imagined to alleviate a 
leaky RyR2; one where a direct interaction with a compound and the β-adrenergic 
receptor is utilized to prevent the catecholamines from binding; this is realized with the 
advent of the so called “β-blockers.” And a second method, where  a direct interaction 
between a compound and RyR2 occurs, one that stabilizes the channel into a more closed 
state, thereby preventing Ca2+ leak. 
β-blockers are high affinity compounds which bind to the β-adrenergic receptor, but do 
not stimulate adenyl-cylcase activity. When bound, they will prevent agonists of the β-
adrenergic receptor, such as the catecholamines, from binding. It has been shown that 
treatment with β-blockers can restore cardiac function, reducing the death rate of patients 
with HF39. Some such β-blockers being used in the treatment of heart failure include: 
Carvedilol, propranolol, metoprolol, and atenolol. 
The other method to decrease diastolic Ca2+ leak during arrhythmias is to directly inhibit 
the intracellular Ca2+ leak by inhibiting RyR2. It has previously been shown that 
compounds such as flecainide40, or benzothiazepine41 will inhibit RyR2, suppressing 
arrhythmias in canine and Langendorff rat hearts.  
Despite these two method’s ability to alleviate arrhythmia, it is unclear how these 
mechanisms are beneficial to heart failure; in normal hearts, inhibition of RyR2 and the 
blockade of the β-adrenergic receptor both lead to a decrease in cardiac output. It has 
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been proposed that the β-blocker carvedilol functions not only by binding to the β-
adregnergic receptor, thereby down-regulating PKA activity, but it also directly inhibits 
RyR2. Specifically, carvedilol has been shown to suppress spontaneous calcium waves, 
also known as stored overload-induced Ca2+ release (SOICR), at concentrations42 similar 
to what we show the catecholamines inhibit RyR2 activity.  
Both the catecholamines and carvedilol are interesting compounds in that they can 
influence RyR2 activity, both on the cell membrane and on RyR2 itself. Carvedilol is 
known to cross the cell membrane43, but it is unlikely that it accumulates to levels within 
the cell that can inhibit RyR2 activity. The catecholamines neither cross the cell 
membrane, nor are present in high enough concentrations in the body to directly 
influence RyR2 activity.  
Despite the problems with these 2 sets of compounds, this research does offer a 
promising insight into the potential development of a new class of compounds. The 
alteration of drugs like the catecholamines or carvedilol may lead to the production of a 
mored lipophilic compound, one that can both inhibit β-adrenergic receptor activity, and 
exist in intracellular concentrations high enough to influence RyR2 activity. Our data 
suggests that making these compounds into better electron donors can alleviate the 
necessity of increasing the amount of compound needed to inhibit RyR2.  
Whether it is possible to modify these compounds without altering the desired effects on 
the system remains to be unseen. Regardless, the development of compounds that can 
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both inhibit RyR2 activity inside the cell, and act as β-blockers could create a new 
frontier in drug development in the prevention of arrhythmia and HF.  
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